Checkpoint Inhibitors Global Market Report 2022 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma), By End-Users (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : 7712 | Delivery Time: 2-3 business days | Format :


The checkpoint inhibitors market consists of sales of the immune checkpoint inhibitor drugs and related services by entities (organizations, sole traders and partnerships) that produce checkpoint inhibitors for treating cancer. A checkpoint inhibitor is a drug that blocks proteins that stop the body’s immune system from killing the cancer cells. One type of cell in the immune system that fights the cancer cells are T-cells. T cells have proteins on them that turn on immune response and other proteins that turn it off. These are called checkpoints. Some checkpoints help T-cells to become active while others help T-cells to switch off. When cancer cells produce high levels of proteins, the switch off checkpoints restrict the immune responses from being strong and sometimes even stops the T-cells from killing the cancer cells. When the checkpoints are blocked by the checkpoint inhibitor from binding with its partner proteins, this allows the T-cells to kill the cancer cells.

The main types of drugs in checkpoint inhibitors are PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cell and others. PD-1 inhibitors and PD-L1 inhibitors are anticancer checkpoint inhibitors which impede the action of the immune checkpoint proteins PD-1 and PDL1 on the cell surface. It is used in lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, others and implemented in various sectors such as hospitals pharmacies, retail pharmacies, online pharmacies.

The global checkpoint inhibitors market size is expected to grow from $19.86 billion in 2021 to $23.93 billion in 2022 at a compound annual growth rate (CAGR) of 20.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The checkpoint inhibitor market is expected to reach $46.27 billion in 2026 at a CAGR of 17.9%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the checkpoint inhibitors market.

The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low-average life expectancy. For instance, the cost for a course of intravenous checkpoint inhibitor therapy is around $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market.

Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion protein or Y-trap. Most of the patients with cancer do not respond to immune checkpoint inhibitors. To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint protein such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells. Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers. This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2020, Targovax, a Norway-based biotechnology company that develops immune activators for targeting solid tumors, entered into a collaboration with Leidos’ Explorations in Global Health (ExGloH) division for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode Microtide™ checkpoint inhibitor peptides.

In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations in Global Health (ExGloH) division of Leidos for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode Microtide checkpoint inhibitor peptides. Explorations in Global Health (ExGloH) division of Leidos has created a specific, proprietary portfolio of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research.

Major players in the checkpoint inhibitors market are AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation.

North America is the largest region in the checkpoint inhibitors market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global checkpoint inhibitors market is segmented -

1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-Cell, Others

2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Others

3) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Checkpoint Inhibitors Market Characteristics

    3. Checkpoint Inhibitors Market Trends And Strategies

    4. Impact Of COVID-19 On Checkpoint Inhibitors

    5. Checkpoint Inhibitors Market Size And Growth

    5.1. Global Checkpoint Inhibitors Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Checkpoint Inhibitors Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Checkpoint Inhibitors Market Segmentation

    6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    PD-1 Inhibitors

    PD-L1 Inhibitors

    CTLA-4

    Chimeric Antigen Receptor T-cell

    Others

    6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Lung Cancer

    Renal Cancer

    Blood Cancer

    Bladder Cancer

    Melanoma

    Others

    6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospitals Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Checkpoint Inhibitors Market Regional And Country Analysis

    7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Checkpoint Inhibitors Market

    8.1. Asia-Pacific Checkpoint Inhibitors Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Checkpoint Inhibitors Market

    9.1. China Checkpoint Inhibitors Market Overview

    9.2. China Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Checkpoint Inhibitors Market

    10.1. India Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Checkpoint Inhibitors Market

    11.1. Japan Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Checkpoint Inhibitors Market

    12.1. Australia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Checkpoint Inhibitors Market

    13.1. Indonesia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Checkpoint Inhibitors Market

    14.1. South Korea Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Checkpoint Inhibitors Market

    15.1. Western Europe Checkpoint Inhibitors Market Overview

    15.2. Western Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Checkpoint Inhibitors Market

    16.1. UK Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Checkpoint Inhibitors Market

    17.1. Germany Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Checkpoint Inhibitors Market

    18.4. France Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Checkpoint Inhibitors Market

    19.1. Eastern Europe Checkpoint Inhibitors Market Overview

    19.2. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Checkpoint Inhibitors Market

    20.1. Russia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Checkpoint Inhibitors Market

    21.1. North America Checkpoint Inhibitors Market Overview

    21.2. North America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Checkpoint Inhibitors Market

    22.1. USA Checkpoint Inhibitors Market Overview

    22.2. USA Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Checkpoint Inhibitors Market

    23.1. South America Checkpoint Inhibitors Market Overview

    23.2. South America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Checkpoint Inhibitors Market

    24.1. Brazil Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Checkpoint Inhibitors Market

    25.1. Middle East Checkpoint Inhibitors Market Overview

    25.2. Middle East Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Checkpoint Inhibitors Market

    26.1. Africa Checkpoint Inhibitors Market Overview

    26.2. Africa Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

    27.1. Checkpoint Inhibitors Market Competitive Landscape

    27.2. Checkpoint Inhibitors Market Company Profiles

    27.2.1. AstraZeneca PLC

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Bristol-Myers Squibb Company

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck & Co., Inc.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Roche Holding AG

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Pfizer

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Checkpoint Inhibitors Pipeline Analysis

    29. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market

    30. Checkpoint Inhibitors Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: AstraZeneca PLC Financial Performance
  • Table 47: Bristol-Myers Squibb Company Financial Performance
  • Table 48: Merck & Co., Inc. Financial Performance
  • Table 49: Roche Holding AG Financial Performance
  • Table 50: Pfizer Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: AstraZeneca PLC Financial Performance
  • Figure 47: Bristol-Myers Squibb Company Financial Performance
  • Figure 48: Merck & Co., Inc. Financial Performance
  • Figure 49: Roche Holding AG Financial Performance
  • Figure 50: Pfizer Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Colorectal Cancer Drugs Global Market Report 2022 – By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies), By Class (Immunotherapy, Chemotherapy) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Breast Cancer Drugs Global Market Report 2022 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others: Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy), By Drug Type (Her2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor), By End User (Amubulatory, Hospitals, Clinics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Drugs For Immunotherapy Global Market Report 2022 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors), By Therapy Area (Cancer, Autoimmune And Inflammatory Diseases, Infectious Diseases), By End User (Hospitals And Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
HER2 Inhibitors Global Market Report 2022 – By Treatment (Monotherapy, Combination Therapy), By Application (Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer), By End User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
HIV Drugs Global Market Report 2022 – By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrate Inhibitors, Fusion Inhibitors, Chemokine Receptor Inhibitors), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Immuno-Oncology Drugs Global Market Report 2022 – By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines), By Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Immunosuppressants Global Market Report 2022 – By Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Interleukin Inhibitors Global Market Report 2022 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)